Returns Breakdown
5.88
Return on Assets
8.28
Return on Investment
| Return on Investment | 8.28 | |
| Return on Assets | 5.88 | |
| Return on Equity | 10.95 | |
| Return Capital | 0.0319 | |
| Return on Sales | 0.0862 |
Here is our Zimmer Biomet (NYSE:ZBH) forecasting for March
 | By Raphi Shpitalnik | Macroaxis Story |
Zimmer Biomet Average Assets are most likely to increase significantly in the upcoming years. The last year's value of Average Assets was reported at 22.1 Billion. The current Earnings before Tax is estimated to increase to about 142.2 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to roughly 1.6 B. The primary intention for this outlook is to break down Zimmer potential for March. We are going to examine if Zimmer Biomet is reasonably priced going into March.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
Over 91.0% of Zimmer Biomet outstanding shares are owned by institutional investors. Institutional ownership of Zimmer Biomet Holdings refers to the amount of Zimmer Biomet Holdings equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Zimmer, including its current ownership diagnostics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Zimmer Biomet. Your research has to be compared to or analyzed against Zimmer Biomet's peers to derive any actionable benefits. When done correctly, Zimmer Biomet's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Zimmer Biomet Holdings.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Zimmer Biomet Holdings. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Zimmer Biomet
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Zimmer Biomet's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Zimmer Biomet's Liquidity
Zimmer Biomet financial leverage refers to using borrowed capital as a funding source to finance Zimmer Biomet Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Zimmer Biomet financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Zimmer Biomet's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Zimmer Biomet's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Zimmer Biomet's total debt and its cash.
Zimmer Biomet Gross Profit
Zimmer Biomet Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Zimmer Biomet previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Zimmer Biomet Gross Profit growth over the last 10 years. Please check Zimmer Biomet's gross profit and other fundamental indicators for more details.
Breaking down Zimmer Biomet Further
Zimmer Biomet Holdings has relatively low volatility with skewness of 2.59 and kurtosis of 13.53. However, we advise all investors to independently investigate Zimmer Biomet Holdings to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Zimmer Biomet Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.